TLCVision (TEAR) to Study DED With the TearLab Osmolarity System

SAN DIEGO, March 10, 2010 (GLOBE NEWSWIRE) — OccuLogix, Inc., dba TearLab Corporation (“TearLab”) (Nasdaq:TEAR) (TSX:TLB), announced today that TLCVision Corporation, North America’s premier eye care services company, will be incorporating the TearLab™ Osmolarity System (“TearLab System”) in eight of its U.S. refractive surgery centers to study Dry Eye Disease (“DED”) symptoms as they relate to LASIK surgery.

The TearLab System is intended to measure the osmolarity of human tears to aid in the diagnosis of DED in conjunction with other methods of clinical evaluation. Using a novel lab-on-a-chip approach, the TearLab System requires less than 50 nL (nanoliters) of tear fluid and displays quantitative osmolarity results in less than 30 seconds. By requiring such a small amount of tears, the TearLab System eliminates the challenges that previously prevented point-of-care osmolarity testing. In addition, it is simple enough to be operated by a technician, greatly improving patient throughput either an office or center setting.

In keeping with its ongoing commitment to provide the best possible outcomes and the highest levels of care for patients, TLCVision will be using the TearLab System to study both pre- and post-operative tear osmolarity levels and treatments with the goal of improving outcomes and reducing post-operative DED symptoms.

Michael A. Lemp, MD, TearLab’s chief medical officer, commented, “Tear hyper-osmolarity is a core mechanism in DED causing damage to the ocular surface and tear osmolarity is a reliable, highly sensitive and specific test for the clinical diagnosis of this disease and a great tool for doctors and a major benefit to patients.”

James B. Tiffany, President and Chief Operating Officer of TLCVision, commented, “TLCVision’s ongoing commitment to clinical services, quality assurance and patient outcomes are unparalleled as the industry leader. We believe that the incorporation of the TearLab System has the potential to improve patient screening, counseling and most significantly the quality of surgical outcome.

About OccuLogix, Inc. dba TearLab Corporation

OccuLogix, Inc. dba TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation’s common shares trade on the NASDAQ Capital Market under the symbol ‘TEAR’ and on the Toronto Stock Exchange under the symbol ‘TLB’.

About TLCVision

TLCVision is North America’s premier eye care services company, providing eye doctors with the tools and technologies needed to deliver high-quality patient care. Through its centers’ management, technology access service models, extensive optometric relationships, direct to consumer advertising and managed care-contracting strength, TLCVision maintains leading positions in Refractive, Cataract and Eye Care markets. Information about vision correction surgery can be found on the TLC Laser Eye Centers’ website at www.tlcvision.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.